Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma

Phase 1

Completed

Conditions: Lymphoma, Large B-Cell, Diffuse
Lymphoma, Follicular

Interventions: Drug: Oral Azacitidine
Drug: Rituximab
Drug: cyclophosphamide
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2015-01-22

Last Posted Date: 2020-08-28

Lead Sponsor: Celgene

Target Recruit Count: 59

Registration Number: NCT02343536

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Weill Cornell Medicine, New York, New York, United States

and more 4 locations

Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: ODM-204
Drug: Prednisone

First Posted Date: 2015-01-22

Last Posted Date: 2019-12-19

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 23

Registration Number: NCT02344017

Locations: 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland
🇱🇻
P. Stradins Clinical University Hospital, Riga, Latvia
🇫🇷
Institut Gustave Roussy, Villejuif, France

and more 1 locations

Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: AIDS-Related Burkitt Lymphoma
HIV Infection
AIDS Related Non-Hodgkin Lymphoma
AIDS-Related Primary Effusion Lymphoma
AIDS-Related Diffuse Large B-cell Lymphoma
AIDS-Related Plasmablastic Lymphoma

Interventions: Drug: Prednisone
Biological: Rituximab
Drug: Etoposide
Drug: Doxorubicin Hydrochloride
Drug: Vincristine Sulfate
Drug: Cyclophosphamide
Biological: Filgrastim
Biological: Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells

First Posted Date: 2015-01-14

Last Posted Date: 2024-01-30

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 10

Registration Number: NCT02337985

Locations: 🇺🇸
NCI Lymphoid Malignancies Branch, Bethesda, Maryland, United States

Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia

Phase 3

Completed

Conditions: Purpura, Thrombocytopenic, Idiopathic

Interventions: Drug: Dexamethasone
Drug: Prednisone

First Posted Date: 2015-01-08

Last Posted Date: 2017-06-09

Lead Sponsor: University Hospital, Essen

Target Recruit Count: 26

Registration Number: NCT02334813

Efficacy of Corticosteroids to Treat Outpatients With Acute Exacerbations of COPD

Phase 4

Completed

Conditions: Pulmonary Disease
Chronic Obstructive (MeSH)

Interventions: Drug: Placebo
Drug: Prednisone

First Posted Date: 2015-01-05

Last Posted Date: 2024-01-10

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 189

Registration Number: NCT02330952

Locations: 🇫🇷
Assistance Publique - Hopitaux Paris, Paris, France

Corticosteroids With Vedolizumab in Crohn's Disease

Phase 4

Terminated

Conditions: Crohn's Disease

Interventions: Drug: Prednisone
Drug: Placebo
Drug: Vedolizumab

First Posted Date: 2014-12-24

Last Posted Date: 2019-04-26

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 1

Registration Number: NCT02324699

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD

Phase 2

Completed

Conditions: Hodgkin Lymphoma

Interventions: Drug: brentuximab vedotin
Drug: Cyclophosphamide
Drug: Adriamycin
Drug: Oncovin
Drug: Bleomycin
Drug: Etoposide
Drug: Procarbazine
Drug: Prednisone
Drug: G-CSF
Radiation: 30 Grays

First Posted Date: 2014-11-21

Last Posted Date: 2021-07-26

Lead Sponsor: The Lymphoma Academic Research Organisation

Target Recruit Count: 40

Registration Number: NCT02298283

Locations: 🇫🇷
CH Sud Francilien, Corbeil-Essonnes, France
🇫🇷
Hôpital André Mignot, Le Chesnay, France
🇫🇷
Centre Léon Bérard, Lyon, France

and more 27 locations

Glucocorticoid in Treatment of Adult Idiopathic Nephrotic Syndrome：a Prospective Observational Study

Not Applicable

Completed

Conditions: Nephrotic Syndrome，Idiopathic

Interventions: Drug: prednisone

First Posted Date: 2014-11-21

Last Posted Date: 2021-01-26

Lead Sponsor: Nanjing University School of Medicine

Target Recruit Count: 235

Registration Number: NCT02298335

Locations: 🇨🇳
Research Institute of Nephrology, Nanjing, Jiangsu, China

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Dexamethasone
Drug: Prednisone
Drug: Methylprednisolone
Drug: Lenalidomide
Drug: Pomalidomide

First Posted Date: 2014-11-19

Last Posted Date: 2023-11-01

Lead Sponsor: Oncotherapeutics

Target Recruit Count: 45

Registration Number: NCT02294357

Locations: 🇺🇸
James R Berenson, MD, Inc., West Hollywood, California, United States
🇺🇸
Blood & Cancer Center of East Texas, Tyler, Texas, United States
🇺🇸
California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States

and more 4 locations

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma

Phase 3

Completed

Conditions: Lymphoma, Large B-Cell, Diffuse

Interventions: Drug: Placebo
Drug: lenalidomide
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: prednisone
Drug: vincristine

First Posted Date: 2014-11-06

Last Posted Date: 2023-06-22

Lead Sponsor: Celgene

Target Recruit Count: 570

Registration Number: NCT02285062

Locations: 🇺🇸
Local Institution - 151, Dallas, Texas, United States
🇺🇸
Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States
🇺🇸
Local Institution - 161, Philadelphia, Pennsylvania, United States

and more 155 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy